What is the 13F Pro Quality Score for SCNX?

13F Pro ranks Scienture Holdings, Inc. (SCNX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View SCNX's current score at https://13fpro.ai/research/SCNX (free sign-up required for the full ranking).

Where does 13F Pro source SCNX data?

All Scienture Holdings, Inc. fundamentals and ownership data come directly from SEC EDGAR. Scienture Holdings, Inc. files with the SEC under CIK 1382574. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is SCNX in?

Scienture Holdings, Inc. (SCNX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is SCNX research updated on 13F Pro?

SCNX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Scienture Holdings, Inc.(SCNX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1382574 SCNX stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $17.1M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

SCNX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Scienture Holdings, Inc. (SCNX), a Healthcare sector company. SCNX is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $17.1m in revenue. Based on the latest XBRL financial filings (Q1 2026), Scienture Holdings, Inc. reports quarterly revenue of $56.3K, net income of $-3.4M, free cash flow of $-2.9M. Top institutional holders of SCNX by reported 13-F value include GEODE CAPITAL MANAGEMENT,, VANGUARD CAPITAL MANAGEMENT, VANGUARD FIDUCIARY CO, based on the most recent SEC filings. SCNX trades on the Nasdaq exchange and files with the SEC under CIK 1382574. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SCNX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Scienture Holdings, Inc. directly from SEC EDGAR.

Revenue

Q1 2026

$56.3K

Net Income

Q1 2026

$-3.4M

Free Cash Flow

Q1 2026

$-2.9M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-68.4% YoY

$431.6KFY 2025

FY21 $9.9MFY22 $10.3MFY23 $1.4MFY25 $431.6K

Net Income

-132.6% YoY

$-41.5MFY 2025

FY21 $-5.3MFY22 $-3.5MFY23 $-17.8MFY25 $-41.5M

Operating Income

-868.8% YoY

$-42.6MFY 2025

FY21 $-5.3MFY22 $-2.9MFY23 $-4.4MFY25 $-42.6M

EPS (Diluted)

+30.6% YoY

$-2.70FY 2025

FY21 $-0.65FY22 $-6.13FY23 $-3.89FY25 $-2.70

Total Assets

+571.7% YoY

$84.2MFY 2025

FY21 $5.8MFY22 $3.7MFY23 $12.5MFY25 $84.2M

Total Debt

—FY 2025

FY21 —FY22 —FY23 —FY25 —

Op. Cash Flow

-501.3% YoY

$-13.4MFY 2025

FY21 $-2.6MFY22 $-1.5MFY23 $-2.2MFY25 $-13.4M

Metric	FY 2025	FY 2023	FY 2022	FY 2021	FY 2019	FY 2018
Revenue	$431.6K -68.4%	$1.4M -86.7%	$10.3M +3.6%	$9.9M +33.0%	$7.4M +94.1%	$3.8M
Net Income	$-41.5M -132.6%	$-17.8M -413.9%	$-3.5M +34.7%	$-5.3M -1769.0%	$-284.4K -3247.0%	$9.0K
Operating Income	$-42.6M -868.8%	$-4.4M -50.8%	$-2.9M +44.9%	$-5.3M -4326.3%	$125.2K +242.9%	$-87.6K
EPS (Diluted)	$-2.70 +30.6%	$-3.89 +36.5%	$-6.13 -843.1%	$-0.65 -1200.0%	$-0.05	$0.00
Total Assets	$84.2M +571.7%	$12.5M +237.8%	$3.7M -35.7%	$5.8M +3.5%	$5.6M +150.1%	$2.2M
Total Debt	—	—	—	—	$225.0K -56.9%	$522.1K
Operating Cash Flow	$-13.4M -501.3%	$-2.2M -45.8%	$-1.5M +40.5%	$-2.6M -1910.1%	$141.8K -48.1%	$273.4K

AI Insight: SCNX Financial Trends

Scienture remains pre-revenue with accelerating losses in Q4 2025, raising questions about cash runway and path to profitability.

• Revenue essentially flat near $0M through Q3 2025; Q4 2025 shows $1M in Q3 2025 only, then disappears again in Q4 2025 and Q1 2026.

• Net loss spiked to $28M in Q4 2025, worst quarter on record, before moderating to $3M in Q1 2026.

• Operating cash flow remained negative across all periods, ranging from $-2M to $-5M; company burning cash consistently.

⚠ Q4 2025 operating loss of $30M signals major charge or restructuring; monitor explanation and sustainability of Q1 2026 improvement.

⚠ Equity declined from $85M (Q3 2024) to $67M (Q1 2026); cumulative net losses eroding balance sheet despite modest debt levels.

AI Insight: SCNX Ratio Trends

Scienture remains unprofitable across all return metrics; TTM ROIC of -63.6% reflects severe capital destruction with no sustained recovery trend.

• ROE oscillated between -62.2% and -15.0% from Q2 2024 through Q3 2025, then spiked to -160.4% in Q4 2025 before recovering to -20.4% in Q1 2026.

• ROIC ranged from -16.4% to -63.6%, with TTM showing deepest losses. Q1 2026 ROIC of -21.0% remains sharply negative.

• Debt-to-equity remained minimal (0.02–0.05 range), indicating low financial leverage but insufficient to offset operational losses.

⚠ Q4 2025 ROE cratered to -160.4%—likely one-time charge or seasonal impact. Sustainability of Q1 2026 stabilization critical.

⚠ No positive ROIC, ROE, or ROA recorded across entire 18-month span. Path to profitability remains opaque.

Get alerted when SCNX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Scienture Holdings, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of SCNX

GEODE CAPITAL MANAGEMENT, LLC
$123.2K432,186 sh
VANGUARD CAPITAL MANAGEMENT LLC
$116.3K408,091 sh
VANGUARD FIDUCIARY TRUST CO
$56.4K198,060 sh
UBS Group AG
$30.7K107,833 sh
XTX Topco Ltd
$13.6K47,680 sh
COMMONWEALTH EQUITY SERVICES, LLC
$12.8K44,798 sh
TWO SIGMA SECURITIES, LLC
$10.4K36,445 sh
JANE STREET GROUP, LLC
$7.9K27,636 sh
Private Advisor Group, LLC
$4.3K15,002 sh
NORTHERN TRUST CORP
$4.0K13,894 sh

Fund	Value	Shares
GEODE CAPITAL MANAGEMENT, LLC	$123.2K	432,186
VANGUARD CAPITAL MANAGEMENT LLC	$116.3K	408,091
VANGUARD FIDUCIARY TRUST CO	$56.4K	198,060
UBS Group AG	$30.7K	107,833
XTX Topco Ltd	$13.6K	47,680
COMMONWEALTH EQUITY SERVICES, LLC	$12.8K	44,798
TWO SIGMA SECURITIES, LLC	$10.4K	36,445
JANE STREET GROUP, LLC	$7.9K	27,636
Private Advisor Group, LLC	$4.3K	15,002
NORTHERN TRUST CORP	$4.0K	13,894

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put SCNX on your watchlist

Track score changes the day Scienture Holdings, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is SCNX a good stock to buy?

13F Pro's AI-powered analysis of Scienture Holdings, Inc. (SCNX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SCNX are available on the SCNX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own SCNX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SCNX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Scienture Holdings, Inc.'s investment landscape.